Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy Nicky A. BeelenFemke A. I. EhlersLotte Wieten Review Open access 19 October 2022 Pages: 797 - 804
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis Kathryn OwenRamy GhalyFiona Thistlethwaite Review Open access 31 October 2022 Pages: 805 - 814
Induction of the activating transcription factor-4 in the intratumoral CD8+ T cells sustains their viability and anti-tumor activities Zhen LuEun-Ah BaeSerge Y. Fuchs Research 05 September 2022 Pages: 815 - 826
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study Marta Español-RegoCarlos Fernández-MartosJoan Maurel Research Open access 09 September 2022 Pages: 827 - 840
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma Wataru FukuokayaTakafumi YanagisawaTakahiro Kimura Research 14 September 2022 Pages: 841 - 849
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer Nabeel KajiharaTakuto KobayashiKen-ichiro Seino Research 14 September 2022 Pages: 851 - 864
Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy Riki OkitaYuka Mimura-KimuraKazunori Okabe Research 17 September 2022 Pages: 865 - 879
PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma Jianhua LiuHao ChenYi-Long Wu Research 19 September 2022 Pages: 881 - 893
Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification Motaz AshkarShruti ChandraRobert R. McWilliams Research 26 September 2022 Pages: 895 - 901
ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth Jing LiChenguang ZhaoJie Qin Research 26 September 2022 Pages: 903 - 916
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer Ke LiJing XuYu Kang Research Open access 27 September 2022 Pages: 917 - 928
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients Tatsuro JoRitsuko Kubota-KoketsuKazuto Shigematsu Research Open access 01 October 2022 Pages: 929 - 944
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival Jeffrey S. WeberTayla PorettaAlexander N. Shoushtari Research Open access 05 October 2022 Pages: 945 - 954
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival Jeffrey S. WeberTayla PorettaAlexander N. Shoushtari Correction Open access 20 December 2022 Pages: 955 - 955
Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement Masaya SuematsuShigeki YagyuTomoko Iehara Research 10 October 2022 Pages: 957 - 968
αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade Mingzhu PanFei WangJuan Zhang Research 13 October 2022 Pages: 969 - 984
Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer Ranran ShiXiuman ZhouYanfeng Gao Research 17 October 2022 Pages: 985 - 1001
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma Lavinia Patricia MocanRares CraciunCarmen Mihaela Mihu Research 17 October 2022 Pages: 1003 - 1014
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function Yu PingJiqi ShanYi Zhang Research 20 October 2022 Pages: 1015 - 1027
Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer Wei GuoQilin HuaiJie He Research Open access 29 October 2022 Pages: 1029 - 1045
Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2 Qingsheng LiKevin E. GogginNejat K. Egilmez Brief Report 08 September 2022 Pages: 1047 - 1058
Correction to: Anti‑PD‑1 antibody‑activated Th17 cells subvert re‑invigoration of antitumor cytotoxic T‑lymphocytes via myeloid cell‑derived COX‑2/PGE2 Qingsheng LiKevin E. GogginNejat K. Egilmez Correction 18 February 2023 Pages: 1059 - 1059
